

PHAR-QA

by PHARMINE

Quality Assurance in European Pharmacy Education and Training.



The Newsletter

September, 2013



Lifelong
Learning
Programme

PHAR-QA Quality Assurance in European Pharmacy Education and Training.

The PHAR-QA newsletter

September, 2013

www.phar-qa.eu

Quality Assurance in European Pharmacy Education and Training: the PHAR-QA project

Editorial Board

Jeffrey **ATKINSON**, Lorraine University, Pharmacolor Consultants Nancy, Villers, France.

Peep **VESKI**, University of Tartu, Estonia.

Daisy **VOLMER**, University of Tartu, Estonia.

Bart **ROMBAUT**, Vrije Universiteit Brussel, Belgium.

Antonio Sanchez **POZO**, University of Granada, Spain.

Dimitrios **REKKAS**, National and Kapodistrian University Athens, Greece.

Jouni **HIRVONEN**, University of Helsinki, Finland.

Borut **BOZIC**, University of Ljubljana, Slovenia

Agnieszka **SKOWRON**, Jagiellonian University, Krakow, Poland.

Constantin **MIRCIOIU**, Universitatea de Medicina si Farmacie "Carol Davila" Bucharest, Romania.

Contents.

Partner 2: PCN-consultants

Page 2

*The May 2013 meeting in Ankara
with the European Association of
faculties of Pharmacy (EAFP)*

Page 6

Correspondence to:

Jeffrey ATKINSON, Lorraine University, Pharmacolor Consultants Nancy, Villers, France

jeffrey.atkinson@univ-lorraine.fr

Partner 2.
PHARMACOLOR consultants
Nancy - PCN



Director:
Jeffrey ATKINSON



PHARMACOLOR consultants Nancy - PCN

Based in Villers, near Nancy in France, Pharmacolor Consultants Nancy (PCN) offers consultancy for projects in the biomedical/pharmaceutical sciences at the European level from preparation through coordination to report writing and dissemination.



Pharmacolor Consultants Nancy (PCN) offers consultancy for projects in the biomedical/pharmaceutical sciences at the European level from preparation through coordination to report writing and dissemination. Documents can be prepared in English or French according to EU or other guidelines.

PCN evolved from "Pharmacolor" a SME that was started in 1986.

Pharmacolor, based in the Pharmacological Laboratory of the Pharmacy Faculty in Nancy, was involved in the preclinical development of many antihypertensive agents such as the calcium entry blockers darodipine, nifedipine and isradipine, the ACE inhibitors captopril, perindopril and ramipril, and the AT1 antagonists telmisartan and candesartan.

Pharmacolor was also involved in the preclinical evaluation of melatonin derivatives.

Pharmacolor also developed several degree courses such as a master in preclinical drug evaluation as well as the "European Summer School in Pharmacology".

PCN offers the following services:

- Preparation and submission of grant proposals to European and other authorities, and management of projects
- Preparation of reports on preclinical drug development and evaluation for government and other agencies

Pharmacolor Consultants Nancy (PCN) peut vous conseiller sur vos projets dans les domaines des sciences biomédicales / pharmaceutiques au niveau européen. Nous pouvons rédiger vos projets, les coordonner et assurer la rédaction de vos rapports en anglais ou en français et leur diffusion. Les documents peuvent être rédigés selon les normes européennes ou d'autres.



PCN a évolué à partir de "Pharmacolor" une PME qui a débuté en 1986.

Pharmacolor, situé dans le Laboratoire de pharmacologie de la Faculté de Pharmacie de Nancy, a été impliqué dans le développement préclinique de nombreux agents antihypertenseurs tels que les inhibiteurs de flux calciques darodipine, la nifédipine et isradipine, les inhibiteurs de l'ECA captopril, le périmopril et ramipril et la AT1 antagoniste le telmisartan.

Pharmacolor a également été impliqué dans l'expertise préclinique de dérivés de la mélatonine.

Pharmacolor a aussi développé plusieurs cursus comme un master d'évaluation préclinique de médicaments ainsi que le « European Summer School in Pharmacology ».

PCN propose les services suivants:

- Préparation et soumission de projets aux autorités européennes et autres, et la gestion de ces projets
- Préparation des rapports sur le développement et l'évaluation précliniques de médicaments pour les autorités gouvernementales et d'autres organismes

Jeffrey ATKINSON, leader partner P2.

Jeffrey ATKINSON (director of Pharmacolor Consultants Nancy (PCN)) was educated at Cambridge University, England and taught cardiovascular pharmacology and therapeutics at the University of California, Davis, California, USA, the "Mario Negri" Pharmacology Institute, Milan, Italy, the Medical Faculty of Lausanne University, Switzerland, and the Pharmacy Faculty of Nancy University, France.

Twenty years ago he created a master degree course in preclinical drug evaluation / safety pharmacology in collaboration with the European pharmaceutical industry and many of the graduates of this course now work in the pharmaceutical and related industries. He also directed preclinical research at the Nestlé Research Laboratories, Lausanne, Switzerland and Rhône-Poulenc Santé, Paris, France.

Whilst working at Nancy University he collaborated extensively with European and American drug companies on the development of several antihypertensive drugs. He sat on the board of many industrial and government research committees in Europe, the USA and Asia. His seminal work includes over 200 publications with a global "h" index of 24.

Jeffrey Atkinson has been working as an expert and evaluator for the EU for over 15 years. He is Emeritus Professor of Pharmacology at Lorraine University, France.

Jeffrey ATKINSON (directeur de Pharmacolor Consultants Nancy (PCN)) a fait ses études à l'Université de Cambridge, en Angleterre, et a enseigné la pharmacologie et la thérapeutique cardiovasculaires à l'Université de Californie, Davis, Californie, Etats-Unis, au "Mario Negri" Institut de pharmacologie, Milan, Italie, à la Faculté de médecine de l'Université de Lausanne, en Suisse, et à la Faculté de pharmacie de l'Université de Lorraine, Nancy, France.

Il a créé, Il y a vingt ans, un master en expertise préclinique des médicaments / pharmacologie de sécurité. Ce master était enseigné en collaboration avec l'industrie pharmaceutique européenne. La plupart des diplômés de ce master travaillent actuellement dans les laboratoires des industriels pharmaceutiques européens. Il a également dirigé la recherche préclinique dans les laboratoires de recherche de Nestlé, à Lausanne, en Suisse et de Rhône-Poulenc Santé, Paris, France.

A l'Université de Lorraine, il a collaboré étroitement avec des entreprises européennes et américaines sur le développement de plusieurs médicaments antihypertenseurs. Il a siégé dans de nombreux comités de recherche en Europe, aux USA et en Asie. Son ouvrage scientifique comprend plus de 200 publications majeures avec un indice « h » de 24 h.

Jeffrey Atkinson a travaillé en tant qu'expert et évaluateur pour l'UE depuis plus de 15 ans.

Il est professeur émérite de pharmacologie à l'Université de Lorraine, France.

Recent scientific publications by Jeffrey Atkinson.

Atkinson, J. Elastin, calcium and age-related stiffening of the arterial wall.

In "PULSE PRESSURE AND ARTERIAL STIFFNESS IN CARDIOVASCULAR PREVENTION", edited by Michel E. Safar, Michael F. O'Rourke, and Edward D. Frohlich. Springer-Medicine. To be published 2013/4. <http://www.springer.com/?SGWID=7-102-0-0-0>

Foulquier, S, et alii. Differential Effects of Short-Term Treatment with Two AT1 Receptor Blockers on Diameter of Pial Arterioles in SHR.

PLOS ONE: 7; 2012. <http://www.plosone.org/>

Foulquier, S, et alii. High salt intake abolishes AT2-mediated vasodilation of pial arterioles in rats.

JOURNAL OF HYPERTENSION Volume: 29 Issue: 7 Pages: 1392-1399. 2011.

<http://journals.lww.com/jhypertension/pages/default.aspx>

Dupuis, et alii. Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat.

JOURNAL OF HYPERTENSION Volume: 28 Issue: 7 Pages: 1566-1573. 2010.

<http://journals.lww.com/jhypertension/pages/default.aspx>

Maizel, et alii. Mechanisms of Aortic and Cardiac Dysfunction in Uremic Mice With Aortic Calcification

CIRCULATION Volume: 119 Issue: 2 Pages: 306-313. 2009. <http://intl-circ.ahajournals.org/>

Recent publications by Jeffrey Atkinson on education.

Jeffrey Atkinson, Bart Rombaut, Antonio Sánchez Pozo, Dimitrios Rekkas, Peep Veski, Jouni Hirvonen, Borut Bozic, Agnieszka Skowron, and Constantin Mircioiu,

A Description of the European Pharmacy Education and Training Quality Assurance Project

Pharmacy 2013, 1 <http://www.mdpi.com/journal/pharmacy>

Jeffrey Atkinson, Jane Nicholson and Bart Rombaut SURVEY OF PHARMACEUTICAL EDUCATION IN EUROPE PHARMINE – Report on the integration of the industry component in pharmacy education and training

europaean INDUSTRIAL PHARMACY June 2012 • Issue 13 <http://www.industrialpharmacy.eipg.eu/>

Atkinson J, Rombaut B. The 2011 PHARMINE report on pharmacy and pharmacy education in the European Union.

Pharmacy Practice (Internet) 2011 Oct-Dec;9(4):169-187. www.pharmacypractice.org

Atkinson J, Rombaut B. The PHARMINE study on the impact of the European Union directive on sectoral professions and of the Bologna declaration on pharmacy education in Europe.

Pharmacy Practice (Internet) 2011 Oct- Dec;9(4):188-194. www.pharmacypractice.org

Guimarães Morais JA, Cavaco AM, Rombaut B, Rouse M, Atkinson J. Quality assurance in European pharmacy education and training.

Pharmacy Practice (Internet) 2011 Oct-Dec;9(4):195-199. www.pharmacypractice.org

Jeffrey Atkinson and Bart Rombaut THE PHARMINE PARADIGM – MATCHING THE SUPPLY OF PHARMACY EDUCATION AND TRAINING TO DEMANDS

europaean INDUSTRIAL PHARMACY • Issue 6 June 2010. <http://www.industrialpharmacy.eipg.eu/>

Hughes, et alii. Improving first-year laboratory classes in bioscience – students' views

UK Centre for Bioscience, Leeds University, UK. <http://www.bioscience.heacademy.ac.uk/>

The May 2013 meeting in Ankara with the European Association of Faculties of Pharmacy (EAFP)



The congress was attended by 185 delegates with many students.

The programme on “Curriculum optimisation” was interesting and gave rise to much in-depth discussion.

J. Atkinson presented the PHAR-QA project to the full assembly

<http://eafponline.eu/conferences/past-meetings/annual-conference-2013->

The PHAR-QA MNGT meeting can be labelled a success for the following reasons:

- Nearly all registered participants actually joined the meeting in Ankara
- The agenda of the meeting was well structured
- There was enough time for discussions, both within the meeting as well as during the breaks
- It is clear that there is still a lot of work and challenges ahead, but the partners have shown in this meeting that they can handle them.
- The most important challenge will be the finalization and launch of the survey.
- Also motivating and re-contacting the relevant (about 100) stake holders of the survey, via the various networks, is understood to be key to its success.
- There was wide agreement within the network for the use of the Basecamp interface for further network communication within PHAR-QA.
- There will be a next meeting in month 13 of the project, held in Brussels (same location as first meeting) **on 14 and 15 November 2013.**

External review by Chris van Schravendijk – Vrije Universiteit Brussel – MEDINE2 WP7L



PHAR-QA Quality Assurance in European Pharmacy Education and Training.

PHAR-QA

by PHARMINE

Quality Assurance in European Pharmacy Education and Training,



Lifelong
Learning
Programme

PHAR-QA Quality Assurance in European Pharmacy Education and Training.